## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## LISTING OF CLAIMS:

1-13. (cancelled)

14. (new) A compound of general formula (I):

$$R_4$$
 $R_5$ 
 $R_5$ 
 $R_2$ 
 $R_3$ 
 $R_3$ 

wherein

- $R_1$  is a hydrogen atom or a  $C_1$ - $C_4$  alkyl group;
- $R_2$  and  $R_3$ , which can be the same or different, are a  $C_1$ - $C_4$  alkyl group, or  $R_2$  and  $R_3$ , together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms or a heterocyclic aliphatic group having 3 to 7 atoms, one or two of which are selected from the group N, O, S and the others being C atoms;
- $R_4$  and  $R_5$ , which can be the same or different, are a hydrogen atom or a  $C_1$ - $C_4$  alkyl group;

- $\mathbf{X}$  is selected from the group consisting of halogen, OR<sub>1</sub>, SR<sub>1</sub>, CN, and a C<sub>1</sub>-C<sub>4</sub> alkyl group;
- **B** has at least one amino group with basic characteristics or a tetraalkylammonium group and is selected from the group consisting of:

- R<sub>6</sub> is a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl group;
- $\mathbf{Y}$  is selected from the group consisting of hydrogen,  $(CH_2)_pY_1$ ,  $(CH_2)_pNR_6Y_1$ ,  $(CH_2)_pN(Y_1)_2$ ,  $NR_5R_6$ ,  $NR_6(CH_2)_pY_1$ , and a residue selected from the group consisting of:

$$(CH_2)pY_1$$
  $(CH_2)pY_1$   $NR_{15}$   $NR_{15}$ 

- ${f T}$  is selected from the group consisting of -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>14</sub>R<sub>18</sub>R<sub>19</sub>, and -OR<sub>6</sub>;
- $R_7$  and  $R_8$ , which can be the same or different, are a hydrogen atom, a  $C_1$ - $C_4$  alkyl group, or  $NR_7R_8$  is a group selected from : i) guanidine optionally substituted with 1 or 2  $C_1$ - $C_4$  alkyl groups, cyclohexyl, ii) a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from O, N, S;

-  $Y_1$  is selected from the group consisting of NR<sub>7</sub>R<sub>8</sub>, NR<sub>14</sub>R<sub>18</sub>R<sub>19</sub>, and a residue selected from the group consisting of:

- **Z** is selected from the group consisting of H,  $C_1$ - $C_6$  alkyl,  $OR_6$ ,  $SR_6$ ,  $CF_3$ ,  $OCOR_6$ ,  $COR_{10}$ ,  $NHCOR_6$ ,  $SO_2R_6$ ,  $SOR_6$ ,  $CO_2R_6$ ,  $N(R_6)_2$ ,  $C_1$ , Pr, Pr,
- $R_9$  is hydrogen or -(CH<sub>2</sub>)q-L, wherein L is selected from the group consisting of -OH, -NR<sub>5</sub>R<sub>6</sub>, -NR<sub>14</sub>R<sub>18</sub>R<sub>19</sub>, amidine optionally substituted with 1 or 2 C<sub>1</sub>-C<sub>4</sub> alkyl groups, and guanidine optionally substituted with 1 or 2 C<sub>1</sub>-C<sub>4</sub> alkyl groups;
- $R_{10}$  is  $OR_6$  or  $NR_6R_{12}$ ;
- $R_{11}$  is selected from the group consisting of hydrogen,  $(CH_2)_q$ -L, and  $-(CH_2)_p$ -NR<sub>4</sub>- $(CH_2)_q$ -L;
- $R_{12}$  is selected from the group consisting of a hydrogen atom, a  $C_1$ - $C_6$  alkyl group, and  $COR_6$ ;
- $R_{13}$  is selected from the group consisting of H, a -C<sub>1</sub>-C<sub>6</sub> alkyl group, -(CH<sub>2</sub>)<sub>p</sub>W(CH<sub>2</sub>)<sub>q</sub>Y<sub>1</sub>, -Y, -COY, and -CH<sub>2</sub>-Y;
- R<sub>14</sub> is a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl group;

- $R_{15}$  is selected from the group consisting of hydrogen and straight or branched  $C_1-C_4$  alkyl groups;
- the  $-NR_{16}R_{17}$  group is a 5-7 membered nitrogen aliphatic heterocycle optionally containing another heteroatom selected from the group consisting of O, S, and N;
- the  $-NR_{14}R_{18}R_{19}$  group is a quaternary ammonium group in which:  $R_{14}$  is selected from the group consisting of straight or branched  $C_1$ - $C_4$  alkyl groups,  $R_{18}$  and  $R_{19}$ , which can be the same or different, are a straight or branched  $C_1$ - $C_4$  alkyl group, or  $NR_{18}R_{19}$  is a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from the group consisting of O, N, and S;
- $\mathbf{W}$  is selected from the group consisting of  $CH_2$ , O, S,  $NR_4$ , and  $N\left(R_4\right)_2$ ;
- p = 1-6, q = 1-6.
  - 15. The compound according to claim 14, wherein,
- B is a residue selected from the group consisting of:

- Y is selected from the group consisting of  $(CH_2)_pY_1$ ,  $(CH_2)_pNR_6Y_1$ ,  $(CH_2)_pN(Y_1)_2$ ,  $NR_5R_6$ , and a residue selected from the group consisting of:

-  $\mathbf{T}$  is -NR<sub>7</sub>R<sub>8</sub>, or OR<sub>6</sub>.

- 16. (new) The compound according to claim 15, wherein,
- R<sub>1</sub> is a hydrogen atom or methyl;
- $R_2$  and  $R_3$ , which can be the same or different, are methyl or ethyl, or  $R_2$  and  $R_3$ , together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms;
- $R_4$  and  $R_5$ , which can be the same or different, are a hydrogen or a methyl;
- x is a chlorine atom;
- **B** is a group selected from the group consisting of:

$$-N$$
 $-R_{13}$ 
 $-N$ 
 $N-R_{13}$ 
 $-N$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 

in which  $R_{13}$  is H or a Y = Y<sub>1</sub> group in which Y<sub>1</sub> is

- $R_{11}$  is selected from the group consisting of hydrogen,  $(CH_2)_q$ -L, and - $(CH_2)_p$ -NR<sub>4</sub>- $(CH_2)_q$ -L, wherein L is selected from the group consisting of -OH, -NR<sub>5</sub>R<sub>6</sub>, amidine optionally substituted with 1 or 2  $C_1$ -C<sub>4</sub> alkyl groups, and guanidine optionally substituted with 1 or 2  $C_1$ -C<sub>4</sub> alkyl groups.
- 17. (new) The compound according to claim 15, wherein,
- $R_2$  and  $R_3$ , which can be the same or different, are methyl or ethyl, or  $R_2$  and  $R_3$ , together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms;
- $R_4$  and  $R_5$ , which can be the same or different, are a hydrogen or a methyl,
- X is a chlorine atom;
- **B** contains at least two amino groups with basic characteristics, in free or salified form, and is selected from the group of:

$$-N$$
 $R_{13}$ 
 $-N$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 

in which  $\mathbf{R}_{13}$  is COY,  $CH_2Y$ ,  $-(CH_2)_pW(CH_2)_qY_1$ ,

- Y is a group (CH<sub>2</sub>)pY<sub>1</sub>, or is selected from:

$$(CH_2)pY_1$$
  $(CH_2)pY_1$ 

wherein T is  $-NR_7R_8$  or  $-OR_6$ ;

- $R_7$  and  $R_8$ , which can be can be the same or different, are selected from the group consisting of a hydrogen atom and a  $C_1$ - $C_4$  alkyl group, or  $NR_7R_8$  is one of i) guanidine optionally substituted with 1 or 2  $C_1$ - $C_4$  alkyl groups, cyclohexyl and ii) a 5-7 membered nitrogen heterocycle optionally containing another heteroatom selected from the group consisting of O, N, and S;
- $\mathbf{Y_1}$  is selected from the group consisting of -NR7R8 and a residue selected from the group consisting of

- $R_9$  is hydrogen or  $-(CH_2)_q$ -L, wherein L is selected from the group consisting of  $-NR_5R_6$ , amidine optionally substituted with 1 or 2  $C_1$ - $C_4$  alkyl groups, and guanidine optionally substituted with 1 or 2  $C_1$ - $C_4$  alkyl groups.
- 18. (new) The compound according to claim 14, containing at least one tetralkyl ammonium, wherein

- R<sub>1</sub> is a hydrogen atom or methyl;
- $R_2$  and  $R_3$ , which can be the same or different, are selected from methyl or ethyl, or  $R_2$  and  $R_3$ , together with the carbon atom which they are linked to, form a cyclic aliphatic group having 3 to 7 carbon atoms;
- $R_4$  and  $R_5$ , which can be the same or different, are a hydrogen or a methyl;
- X is a chlorine atom;
- ${\bf B}$  is selected from the group consisting of NR<sub>6</sub>Y and from the residues:

$$-N$$
 $-R_{13}$ 
 $-N$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 
 $N-R_{13}$ 

-  $\mathbf{Y}$  is selected from the group consisting of Y, COY,  $(CH_2)_pY_1$ ,  $NR_6(CH_2)_gY_1$  and a residue selected from the group consisting of:

$$(CH_2)pY_1$$
  $(CH_2)pY_1$   $T$   $NHR_{11}$ 

- ${f T}$  is selected from the group consisting of -NR<sub>7</sub>R<sub>8</sub>, NR<sub>14</sub>R<sub>18</sub>R<sub>19</sub>, and -OR<sub>6</sub>;
- $Y_1$  is selected from the group consisting of -NR<sub>7</sub>R<sub>8</sub>, -NR<sub>7</sub>R<sub>8</sub>R<sub>14</sub> or from the following residues:

- 19. (new) The compound according to claim 14, wherein the compound is selected from the group consisting of:
- N-[2-[4-(2-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzensulfonamide trifluoroacetate;
- N-{2-[4-(6-guanidinohexyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)benzenesulfonamido -2-methyl-propionamide tris trifluoroacetate;
- 4-{2-[2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzene-sulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine;
- N-[2-[4-(2-(S)-amino-5-guanidino-pentanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{2-[4-(6-aminohexyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{2-[4-(piperazin-2-yl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;

- N-{2-[4-(piperazin-1-ylacetyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzene-sulfonamide bis trifluoroacetate;
- N-(2-[4-2-(piperidin-4-yl-acetyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzene-sulfonamide bis trifluoroacetate;
- N-{2-[4-[N-(4-piperidyl)glycyl]-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzene-sulfonamide tris trifluoroacetate;
- N-{2-[4-(4-(2-aminoethyl)piperazin-1-yl)acetyl)piperazin-1-yl}-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tetra
  trifluoroacetate;
- N-{2-[4-(3-(R)-Amino-6-guanidino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-{2-[4-(3-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3-(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris trifluoroacetate;

- N-{2-[4-(3-(S)-amino-7-dimethylamino-heptanoyl)piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3(2-methyl-8-quinolinoxymethyl)-benzenesulfonamide tris
  trifluoroacetate;
- N-(3-Amino-propyl)-4-{2-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine tris trifluoroacetate;
- N-[2-[4-(2-(S)-amino-5-dimethylamino-pentanoyl))piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4-dichloro-3(2-methyl-8-quinolinoxy-methyl)-benzenesulfonamide tris
  trifluoroacetate;
- (S)-N-{2-[1'-(2-Amino-5-guanidino-pentanoyl)[4,4']bipiperidinyl-1-yl]-1,1-dimethyl-2-oxo-ethyl}-2,4dichloro-3-(2-methyl-quinolin-8-yloxymethyl)benzenesulfonamide;
- 2,4-Dichloro-N-(2-{4-[2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-3,5-dimethyl-piperazin-1-yl}-1,1-dimethyl-2-oxo-ethyl)-3-(2-methyl-4a,8a-dihydro-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-(2-{4-[4-(2-(S)Amino-5-guanidino-pentanoyl)-piperazin-1-yl]-piperidin-1-yl}-1,1-dimethyl-2-oxo-ethyl)-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide;

- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)benzenesulfinic acid [1-(4-piperazin-1-yl-piperidine-1carbonyl)-cyclopentyl]-amide;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)benzenesulfinic acid (1-{4-[4-(2-S-amino-6-guanidinohexanoyl)-piperazin-1-yl]-piperidine-1-carbonyl}cyclopentyl)-amide;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)benzenesulfinic acid (1-{4-[4-(2-S-amino-5-guanidinopentanoyl)-piperazin-1-yl]-piperidine-1-carbonyl}cyclopentyl)-amide;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)benzenesulfinic acid [1-(4-piperidin-4-yl-piperazine-1carbonyl)-cyclopentyl]-amide;
- 2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)benzenesulfinic acid {2-[4-(2-guanidino-ethyl)-piperazin1-yl]-1,1-dimethyl-2-oxo-ethyl}-amide;
- 2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)
  benzenesulfinic acid (2-{4-[2-S-amino-5-(N',N''-diethylquanidino)-pentanoyl]-piperazin-1-yl}-1,1-dimethyl-2-oxoethyl)-amide;
- 2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)
  benzenesulfinic acid (2-{4-[2-R-amino-5-(N',N''-diethylguanidino)-pentanoyl]-piperazin-1-yl}-1,1-dimethyl-2-oxoethyl)-amide;

- (2S)-N-(1-{4-[2-Amino-6-(N',N''-diethyl-guanidino)-hexanoyl]-piperazine-1-carbonyl}-cyclopentyl)-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-(1-{4-[2-(S)Amino-6-(N',N''-diethyl-guanidino)pentanoyl]-piperazine-1-carbonyl}-cyclopentyl)-2,4dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)benzenesulfonamide;
- N-[2-[4-(2-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2,4dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-[2-[4-(3-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2,4dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-[2-[4-(3-(S)-Amino-6-dimethylamino-heptanoyl)piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3(2,4-dimethyl-quinolin-8-yloxy methyl)benzenesulfonamide;
- N-[2-[4-(2-(S)-Amino-5-guanidino-pentanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-[2-[4-(2-(S)-Amino-6-guanidino-hexanoy1)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide;

- N-[2-[4-(2-(S)-Amino-5-dimethylamino-pentanoyl))piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-[2-[4-(2-(R)-Amino-5-guanidino-pentanoy1)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonamide;
- N-[2-[4-(3-(S)-Amino-6-guanidino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonamide;
- N-[2-[4-(3-(S)-Amino-7-guanidino-heptanoy1)-piperazin-1-y1]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonamide;
- N-{2-[4-(4-2(Guanidino)ethyl]piperazin-lylacetyl)piperazin-l-yl]-1,l-dimethyl-2-oxo-ethyl]-2,4-dichloro-3(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide;
- N-[1-[4-(2-(S)-Amino-5-guanidino-pentanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(2-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(2-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2-methyl-quinolin-8yloxymethyl)-benzenesulfonamide tris trifluoroacetate;

Docket No. 2503-1135 Appln. No. 10/516,681

- N-[1-[4-(2-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tristrifluoroacetate;
- N-[1-[4-(2-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- (R)-N-[4-(2-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tristrifluoroacetate;
- (R)-N-[1-[4-(2-(S)-Amino-6-dimethylamino-hexanoyl)piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide
  tris trifluoroacetate;
- N-{2-[4-(4-2(Guanidino)ethyl]piperazin-lylacetyl)piperazin-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tetra
  trifluoroacetate;
- N-[1-[4-(2-(R)-Amino-6-amino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tristrifluoroacetate;
- N-[1-[4-(2-(R)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-

- quinolin-8-yloxymethyl)-benzenesulfonamide tris
  trifluoroacetate;
- N-[2-[4-(3-(S)-Amino-6-guanidino-hexanoyl)-piperazin-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tristrifluoroacetate;
- N-[2-[4-(3-(S)-Amino-6-dimethylamino-hexanoyl)-piperazin-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris trifluoroacetate;
- N-[1-[4-(6-Guanidino-hexanoyl)-piperazine-1-carbonyl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzene-sulfonamide bis trifluoroacetate;
- N-[2-[4-(2-(S)-Amino-6-amino-hexanoyl)-piperazin-1-yl]1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methylquinolin-8-yloxymethyl)-benzenesulfonamide tris
  trifluoroacetate;
- N-[2-[4-(2-(S)-Guanidino-6-guanidino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonamide tris trifluoroacetate;
- (R)-N-[4-(3-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxy-methyl)-benzene sulfonamide tristrifluoroacetate;

- (R)-N-{2-[4-(4-2(Guanidino)ethyl]piperazin-lylacetyl)piperazin-l-carbonyl]--1-methyl-propyl]-2,4-dichloro-3(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide
  tetra trifluoroacetate;
- (R)-N-[4-(3-(S)-Amino-6-amino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tristrifluoroacetate;
- (R)-N-[4-(3-(S)-Guanidino-6-guanidino-hexanoyl)piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide
  tris trifluoroacetate;
- (R)-N-[4-(3-(S)-Amino-6-dimethylamino-hexanoyl)piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide
  tris trifluoroacetate;
- (S)-N-[4-(2-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxy-methyl)-benzenesulfonamide tristrifluoroacetate;
- (S)-N-[4-(3-(S)-Amino-6-guanidino-hexanoyl)-piperazine-1-carbonyl]-1-methyl-propyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxy-methyl)-benzenesulfonamide tristrifluoroacetate;

- 2,4-Dichloro-N-{1-[4-(3(S),6-diamino-hexanoyl)piperazine-1-carbonyl]-cyclopentyl}-3-(2,4-dimethylquinolin-8-yloxymethyl)-benzenesulfonamide tris
  trifluoroacetate;
- 2,4-Dichloro-N-{1-[4-(3(S),6-diguanidino-hexanoyl)piperazine-1-carbonyl]-cyclopentyl}-3-(2,4-dimethylquinolin-8-yloxymethyl)-benzenesulfonamide tris
  trifluoroacetate;
- N-(1-{4-[3-(S),6-Bis-(N',N''-dicyclohexyl-guanidino)-hexanoyl]-piperazine-1-carbonyl}-cyclopentyl)-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzensulfonamide tris trifluoroacetate;
- N-{1-[4-(2-(S)Amino-3-piperidin-4-yl-propionyl)piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris
  trifluoroacetate;
- N-{1-[4-(2-Trimethylammonium-acetyl)-piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide bistrifluoroacetate;
- N-{1-[4-(4-Trimethylammonium-butanoyl)-piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide bistrifluoroacetate;

- N-{1-[4-(3(R)-Hydroxy-4-trimethylammonium-butanoyl)piperazine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4dimethyl-quinolin-8-yloxy-methyl)-benzenesulfonamide bis
  trifluoroacetate;
- N-[1-[4-(2-(S)-Dimethylamino-6-dimethylamino-hexanoyl)piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4dimethyl-quinolin-8-yloxy-methyl)-benzenesulfonamide tris
  trifluoroacetate;
- {5-[(1-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzensulfonylamino]-cyclopentanecarbonyl}-piperidin-4-ylmethyl)-dimethyl-ammonium]pentyl}trimethyl-ammonium tris trifluoroacetate;
- {5-[(1-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzensulfonylamino]-cyclopentanecarbonyl}piperidine-4-carbonyl)-amino]-pentyl}-trimethyl-ammonium
  bis trifluoroacetate;
- N-[1-[4-(2-(S)-Trimethylammonium-6-trimethylammonium-hexanoy1)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamidetris trifluoroacetate;
- N-[1-[4-(2-(R)-Trimethylammonium-6-trimethylammonium-hexanoyl)-piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamidetris trifluoroacetate;

- N-[1-[4-(2-(S)-Trimethylammonium-6-amino-hexanoyl)piperazin-1-yl]-cyclopentyl]-2,4-dichloro-3-(2,4dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tris
  trifluoroacetate;
- N-{1-[4-(6-Trimethylammonium-hexanoyl)-piperazine-1-carbonyl]-cyclopentyll}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide bistrifluoroacetate;
- N-(6-Amino-hexyl)-4-{2-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-benzenesulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine;
- N-[2-(3-Amino-propylamino)-ethyl]-4-{2-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-2-methyl-propionyl}-piperazine-1-carboxamidine;
- N-(3-Amino-propyl)-4-{2-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino}-2-methyl-propionyl}-piperazine-1-carboxamidine bis trifluoroacetate;
- N-(6-Amino-hexyl)-4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]
  cyclopentanecarbonyl}-piperazine-1-carboxamidine bis

  trifluoroacetate;
- N-[2-(3-Amino-propylamino)-ethyl]-4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-

benzenesulfonylamino]-cyclo-pentanecarbonyl}-piperazine1-carboxamidine bis trifluoroacetate:

- N-[2-(4-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}piperazin-1-yl)-ethyl]-4-methyl-piperazine-1carboxamidine bis trifluoroacetate;
- 2,4-Dichloro-N-{1-[4-(2(R),6-diamino-hexyl)-piperazine-1carbonyl]-cyclopentyl}-3-(2,4-dimethyl-quinolin-8yloxymethyl)-benzene-sulfonamide tetra trifluoroacetate;
- 2,4-Dichloro-N-{1-[4-(2(R),6-diguanidino-hexyl)-piperazine-1-carbonyl]-cyclopentyl}-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tetrahydrochloride
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N- {1-[4-(2-piperazin-1-yl-ethyl)-piperazine-1-carbonyl]- cyclopentyl}-benzenesulfonamide tetra trifluoroacetate;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N{1-[4-(2-piperidin-4-yl-ethyl)-piperazine-1-carbonyl]cyclopentyl}-benzene-sulfonamide;
- {3-[(4-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}piperazine-1-carboximi-doyl)-amino}propyl}-trimethylammonium tris trifluoroacetate;
- 4-{1-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzene-sulfonylamino]-

- cyclopentanecarbonyl}-N-(3-dimethylamino-propyl)piperazine-1-carboxamidine tris trifluoroacetate;
- N-(1-{4-[(5-Amino-pentylamino)-methyl]-piperidine-1-carbonyl}-cyclopentyl)-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tristrifluoroacetate;
- N-{1-[4-(4-Amino-piperidin-1-ylmethyl)-piperidine-1-carbonyl]-cyclopentyl}-2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonamide tristrifluoroacetate;
- 2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-N(1-{4-[(5-methylamino-pentylamino)-methyl]-piperidine-1carbonyl}-cyclopentyl)-benzenesulfonamide tris
  trifluoroacetate; and
- Amino-6-(4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}piperazin-1-yl)-6-oxo-hexyl]-trimethyl-ammonium bis
  trifluoroacetate.

20. (new) An intermediate of general formula (6) or (7)

$$R_4$$
 $R_5$ 
 $CI$ 
 $R_1$ 
 $CI$ 
 $R_1$ 
 $CI$ 
 $R_1$ 
 $CI$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $CI$ 
 $R_5$ 
 $R_5$ 
 $R_5$ 
 $R_7$ 
 $R_8$ 
 $R_8$ 
 $R_8$ 
 $R_8$ 
 $R_9$ 
 $R_9$ 
 $R_9$ 
 $R_9$ 
 $R_9$ 
 $R_9$ 
 $R_9$ 
 $R_9$ 

in which  $R_1$  can be H or methyl,  $R_2$  and  $R_3$  can be independently methyl, ethyl or, together with the carbon atom which they are linked to, form a cyclopentyl group, and  $R_{14}$  is methyl or t-butyl.

## 21. (new) An intermediates of general formula (1)

$$R_4$$
 $R_5$ 
 $CI$ 
 $R_1$ 
 $R_3$ 
 $R_4$ 
 $R_5$ 
 $R_5$ 
 $R_1$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_5$ 
 $R_5$ 
 $R_1$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_5$ 
 $R_5$ 
 $R_1$ 
 $R_2$ 
 $R_3$ 
 $R_4$ 
 $R_5$ 

in which  $R_1$  can be H or methyl,  $R_2$  and  $R_3$  can be independently methyl, ethyl or, together with the carbon atom which they are linked to, form a cyclopentyl group.

- 22. (new) A pharmaceutical composition containing as an active ingredient a compound as claimed in any one of claims 14 to 19, together with pharmaceutically acceptable excipients.
- 23. (new) A method for the treatment of inflammation, asthma, chronic bronchitis, allergic rhinitis or obstructive pulmonary disease (COPD) in a subject in need thereof, which comprises administering to said subject a therapeutically effective amount of a compound according to claim 14.